Filing Flows

Filing Flows › Companies › RxSight › Cash flow

RxSight cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$44.0M in Q3 2026 · $18.6M over twelve months

Operating cash flow$45.2M
Capital spending−$1.2M
Free cash flow+$44.0M
Cash conversion cycle541 days

Analysis

In Q3 2026, RxSight generated $45.2M of operating cash flow and spent $1.2M on capital projects, leaving free cash flow of $44.0M. That is $45.8M more than in Q3 2025 (−$1.8M).

Over the twelve months to Sep 30, 2026, operating cash flow was $23.7M; the largest uses were capital spending ($5.0M), other financing ($500K), net borrowing (+) / repaid (−) ($12K); besides operations, cash came from other investing ($16.9M), shares issued ($2.1M); the cash balance rose by $37.1M.

Operating cash flow was $45.2M against net income of −$16.2M. The largest differences: stock-based pay +$7.6M, inventory −$4.6M, payables −$3.0M.

Its cash conversion cycle was 541 days (receivables 66 + inventory 544 − payables 69).

Free cash flow

RxSight: free cash flow by quarterRxSight: free cash flow by quarter−$5.1MQ4 2024−$9.4MQ1 2025−$5.9MQ2 2025−$1.8MQ3 2025−$2.3MQ4 2025−$11.7MQ1 2026−$11.5MQ2 2026$44.0MQ3 2026
Operating cash flow less capital spending.
RxSight: operating cash flow against capital spendingRxSight: operating cash flow against capital spendingOperating cash flowCapital spending−$4.3M$847KQ4 2024−$8.8M$575KQ1 2025−$4.4M$1.5MQ2 2025−$1.2M$581KQ3 2025−$1.1M$1.1MQ4 2025−$10.9M$759KQ1 2026−$9.5M$2.0MQ2 2026$45.2M$1.2MQ3 2026
Latest (Q3 2026): Operating cash flow $45.2M, Capital spending $1.2M.

Capital allocation, year by year

RxSight: where the cash came from (up) and went (down), by fiscal yearRxSight: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$44.7MFY2021: Net borrowing $15.0MFY2021: Shares issued $14.0MFY2021: Capital spending −$1.9M$28.9MFY2021FY2022: Operating cash flow −$58.9MFY2022: Net borrowing −$121KFY2022: Shares issued $1.8MFY2022: Capital spending −$2.4M$1.8MFY2022FY2023: Operating cash flow −$41.6MFY2023: Net borrowing $19.8MFY2023: Shares issued $9.5MFY2023: Capital spending −$4.8M$29.3MFY2023FY2024: Operating cash flow −$16.9MFY2024: Net borrowing −$61KFY2024: Shares issued $20.8MFY2024: Capital spending −$5.4M$20.8MFY2024FY2025: Operating cash flow −$15.5MFY2025: Net borrowing −$26KFY2025: Shares issued $4.0MFY2025: Capital spending −$3.8M$4.0MFY2025
Over these 5 years operating cash flow totalled −$178M; the largest uses were operating cash flow ($178M) and capital spending ($18.4M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$255M
Debtnone
Net cash$255M

RxSight funds itself: free cash flow was $18.6M over the last twelve months, with $255M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

RxSight: sources (+) and uses (−) of cash, Q3 2026RxSight: sources (+) and uses (−) of cash, Q3 2026Cash drawn (+) / kept (−)−$53.4MOperating cash flow$45.2MOther investing$9.1MCapital spending−$1.2MShares issued$227KOther financing−$25KExchange rates$8KNet borrowing (+) / repaid (−)−$7K
RxSight: sources (+) and uses (−) of cash, TTM to Q3 2026RxSight: sources (+) and uses (−) of cash, TTM to Q3 2026Cash drawn (+) / kept (−)−$37.1MOperating cash flow$23.7MOther investing$16.9MCapital spending−$5.0MShares issued$2.1MOther financing−$500KNet borrowing (+) / repaid (−)−$12KExchange rates−$1KNot reconciled−$1K

From profit to cash

RxSight: net income to operating cash flow, Q3 2026RxSight: net income to operating cash flow, Q3 2026Net income−$16.2MDepreciation & amortization$929KStock-based pay$7.6MReceivables$1.6MInventory−$4.6MPayables−$3.0MAccrued liabilities−$1.0MDeferred revenue−$40KPrepaid and other assets−$135KOperating cash flow$45.2M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20266654469541
Q2 20265541778394
Q1 20266740476395
Q4 20256737954392
Q3 20257940651435
Q2 20258026256285
Q1 20257221455232
Q4 20246317637203

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$45.2M−$1.2M−$7K$227K−$53.4M$44.0M
Q2 2026−$9.5M−$2.0M−$7K$669K$4.2M−$11.5M
Q1 2026−$10.9M−$759K−$7K$144K$2.4M−$11.7M
Q4 2025−$1.1M−$1.1M$9K$1.1M$9.7M−$2.3M
Q3 2025−$1.2M−$581K−$19K$131K$10.7M−$1.8M
Q2 2025−$4.4M−$1.5M−$3K$2.1M−$12.4M−$5.9M
Q1 2025−$8.8M−$575K−$13K$696K−$11.3M−$9.4M
Q4 2024−$4.3M−$847K−$12K$3.0M−$24K−$5.1M

RxSight: income statement and cash flow

RxSight, Q3 2026: revenue $24.6M (-19% year over year), operating margin -75.3%. The chart follows the revenue to costs, profit and cash.

RxSight: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.